Not long ago, life science companies were flush with cash and eager to ink deals. Now, they’re taking a more calculated approach to growth. With patent cliffs looming, high interest rates holding steady, and ongoing policy shifts in the U.S. healthcare sector, the dealmaking landscape has become a high-stakes arena. Today, there are fewer, but larger, transactions as companies aim to select targets that can deliver transformative growth. The challenge ahead lies in striking the right balance between bold bets on high-potential assets and cautious investment in a climate of uncertainty. Here’s a look at how companies are increasing the depth of their portfolios without taking on the heavy costs of in-house development.
Read the full article: How Pharma Is Reinventing Its Growth Strategy through M&A //
Source: https://www.definitivehc.com/blog/pharma-cost-saving-market-share-strategies